Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
Qui est le CEO de Prostatype Genomics AB ?
Fredrik Persson est le Chief Executive Officer de Prostatype Genomics AB, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action PGABF ?
Le prix actuel de PGABF est de $0, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Prostatype Genomics AB ?
Prostatype Genomics AB appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Prostatype Genomics AB ?
La capitalisation boursière actuelle de Prostatype Genomics AB est de $0
